-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Is It Smart To Buy Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Before It Goes Ex-Dividend?
Is It Smart To Buy Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) Before It Goes Ex-Dividend?
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Joinn Laboratories(China)Co.,Ltd. (SHSE:603127) is about to go ex-dividend in just two days. The ex-dividend date is one business day before the record date, which is the cut-off date for shareholders to be present on the company's books to be eligible for a dividend payment. The ex-dividend date is an important date to be aware of as any purchase of the stock made on or after this date might mean a late settlement that doesn't show on the record date. In other words, investors can purchase Joinn Laboratories(China)Co.Ltd's shares before the 8th of August in order to be eligible for the dividend, which will be paid on the 8th of August.
The company's next dividend payment will be CN¥0.36 per share, and in the last 12 months, the company paid a total of CN¥0.36 per share. Based on the last year's worth of payments, Joinn Laboratories(China)Co.Ltd stock has a trailing yield of around 0.3% on the current share price of CN¥118.11. Dividends are an important source of income to many shareholders, but the health of the business is crucial to maintaining those dividends. We need to see whether the dividend is covered by earnings and if it's growing.
See our latest analysis for Joinn Laboratories(China)Co.Ltd
Dividends are typically paid from company earnings. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. Joinn Laboratories(China)Co.Ltd is paying out just 23% of its profit after tax, which is comfortably low and leaves plenty of breathing room in the case of adverse events. Yet cash flows are even more important than profits for assessing a dividend, so we need to see if the company generated enough cash to pay its distribution. Luckily it paid out just 21% of its free cash flow last year.
It's encouraging to see that the dividend is covered by both profit and cash flow. This generally suggests the dividend is sustainable, as long as earnings don't drop precipitously.
Click here to see the company's payout ratio, plus analyst estimates of its future dividends.
SHSE:603127 Historic Dividend August 5th 2022Have Earnings And Dividends Been Growing?
Companies with consistently growing earnings per share generally make the best dividend stocks, as they usually find it easier to grow dividends per share. If business enters a downturn and the dividend is cut, the company could see its value fall precipitously. It's encouraging to see Joinn Laboratories(China)Co.Ltd has grown its earnings rapidly, up 46% a year for the past five years. Joinn Laboratories(China)Co.Ltd looks like a real growth company, with earnings per share growing at a cracking pace and the company reinvesting most of its profits in the business.
Another key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. In the last four years, Joinn Laboratories(China)Co.Ltd has lifted its dividend by approximately 47% a year on average. It's great to see earnings per share growing rapidly over several years, and dividends per share growing right along with it.
Final Takeaway
Should investors buy Joinn Laboratories(China)Co.Ltd for the upcoming dividend? We love that Joinn Laboratories(China)Co.Ltd is growing earnings per share while simultaneously paying out a low percentage of both its earnings and cash flow. These characteristics suggest the company is reinvesting in growing its business, while the conservative payout ratio also implies a reduced risk of the dividend being cut in the future. Overall we think this is an attractive combination and worthy of further research.
On that note, you'll want to research what risks Joinn Laboratories(China)Co.Ltd is facing. To help with this, we've discovered 3 warning signs for Joinn Laboratories(China)Co.Ltd that you should be aware of before investing in their shares.
Generally, we wouldn't recommend just buying the first dividend stock you see. Here's a curated list of interesting stocks that are strong dividend payers.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
一些投资资者靠依分红来加财富,果你的些些些些息息探之之你,可用道最好道一这会一这会 乔恩实验室(中国)有公司,有公司,有公司 如果您有任何問題,請聯系我們的客服人員。除日息是记录日期前一个工作日,这是股东在公文中获资源簿有上格得得止止期日。除日息息是需要要要注注意意的日期,因為在該日或之後买的任何何人意票可意味已能使用记录日延延迟日。句换话说,投票者可以在 8 月 8 月 8 日购买中茵实验室有限公司的限公司股票,以分红的格,将分红的格,将股于 8 月 8 日付息日。
该公司下的一次次股息将为股 0.36 人,过在的 12 个月中,公该司共支付付每股 0.36 人民币。根据去年的付款費用,昭衍制藥有(中国)限公司有公司股票的尾隨收集益为约人币 118.11 元股的价。股是息许多股股東的東收入来源,但业务务的健康对这些于维这些关至分红要。我们需要看看看看看是否有收益支付,股及否是在增长。
查看看我们对中衍实验室(中国)有限公司的最新分分
股息常从公司益益中支付。如果一家公司支付的股息息多得那麼润,分是红不可用可能持的续。昭衍藥物(中国)制造有限公司限公司僅限付税利润的 23%,这相当当低,在发发发在生良性不利于出口足充填息的喘空间。而,在评评股估息时,金现甚至比利润更要,因此我就要看要要看所需要的公文是否产产生足够的金现付支支付流。幸運是的,它去僅年支付自自金现流的 21%。
令人鼓舞的是,股息息息利润和现流共同支付。通通常表明,只要要益益不急剧下降降,股是可续续的。
击此处处查查该看公派司的率派派息,以及师其未来息的计。
如果你想要更多的話,你可以在這裡找到你想要的東西。益收和股息一直在增长吗?
每股收收益持续增长的公司常是最好的股息,常常为发现现增加加加上股更息容易他。如果业务务进进入低迷状态并削减重股息,公公司价价的值可急会剧下降。令人鼓舞的是,昭衍制藥股份有限公司(中国)限公司公司的收益增长速迅,过去去五年每年增长 46%。昭衍實驗室(中国)限公司限公司看一家正的成長型態發起,每收費司惊人的速度增人口增度增長,該公文將利分配润该收藏。
衡量公公股司息前的景一种关键法衡量量其史增息息长。率在过去去的四年中,昭衍制药有限公司(中国有)限公司均每年将平息息提高约 47%。很高兴看到每股益益在年几内迅速增长,每股股股也息随增长。
最后的外卖卖
资资者投是应该购收中衍制药公司(中国)有限公司以得得将分红的人来?我们喜欢昭衍实验室(中国)有限公司每股收益益的增同,时支的付付现现和流的比都很金很少。些这特征务表该明公司正在进行再再资发发发以其他人,而保保的息息也意味着着着着着用来削的险风低。总的来说,我为为这个儿儿认引力力的组合,值得进步步步。
就此而言,你需要研究一下昭衍實驗室(中国)有公司公司臨风的险。为了帮助助解这个问题,们现发了了发 乔乔实验室(中国)限公公司志的 3 个个 在投资他他的股票之前,你应该意这这一点。
常通,我们不建议议买只入你看到的第一只股息。里这是 一份精选的股息支强劲的有趣票股清单。
对这篇文章有反馈吗?对内容感到担担忧? 取联得系 接直和们我联系系。 或者,给编团队队 (在) 簡易壁紙網发电电邮件件。
簡單的牆壁聖羅的文章本质质一般上性的。 我仅仅使用用不易倚的方法根据历历数据和分析师师测评我论的们们们们的们们并文并非非在旨旨提供建财议。 它不作作成务买或卖出何股票何没票的建议,也有考标您的目财或状况。我们的目标是为您提供由基本动面驱的长点点分析析。请注意,们我的析分能可未将最新的人性价為感公司定義或考考材材材虑在内。简而言之,华街对上任何何票都没有头。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧